A Novel Highly Bioavailable Curcumin Formulation Improves Symptoms And Diagnostic Indicators In Rheumatoid Arthritis Patients: A Randomized, Double-Blind, Placebo-Controlled, Two-Dose, Three-Arm, And Parallel-Group Study
|Values||(g/L). Within group. Placebo: before 38.8 ± 3.8, after 38.1 ± 3.8. Low dose: before 39.2 ± 4.7, after 39.4 ± 3.4. High dose: before 45.4 ± 7.8, after 45.1 ± 7.8|
|Trial Design||Randomized trial|
|Trial Length||1-6 months|
|Number of Subjects||36|
|Age Range||18-29, 30-44, 45-64, 65+|
|Body Types||Obese, Overweight, Average, Underweight|
In a randomized, double-blind, placebo-controlled trial, 36 participants were assigned to take placebo, 500 mg, or 1,000 mg of a bioavailable curcuminoid extract (95% curcuminoids) for 3 months.Funding issues for this study:
The primary outcome was the efficacy of curcuminoids for reducing the symptoms if rheumatoid arthritis, as measured by DAS-28. The curcumin groups saw large reductions in their scores, which were statistically significant) within group), while the placebo group saw no change. The high dose group saw a greater reduction than the low dose group, but between-group statistics weren't provided. The same was the case for evaluation of pain on the vidual analog scale.
The improvement in American College of Rheumatology assessment was large, statistically significant, and comparable for the curcumin groups, while the placebo group saw no improvement.
There were no serious adverse events reported, and blood tests didn't reveal any worrying effects from curcumin.
The curcumin groups saw a large, statistically significant reduction in c-reactive protein, with the high dose group seeing a greater reduction, while the placebo group saw a small increase which wasn't statistically significant. The reduction in erythrocyte sedimentation rate was dramatic for the curcumin groups, which was statistically significant for both, and with no notable difference between them. The placebo group saw a decrease which wasn't statistically significant or as great as the curcumin groups.
"The authors gratefully thank the management of Plant Lipids Ltd., Cochin, India, which developed and provided the study product (Acumin). They express their appreciation to the laboratory members for their active help and cooperation. Four of the authors (A.A., K.V., J.J., and S.G.) are employees of Aurea BioLabs Ltd., a research subsidiary of Plant Lipids Ltd. All other authors have no conflicts to report."